Highly-selective μ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model

Mitchell J. Bartlett, Lisa Y. So, Lajos Szabò, David P. Skinner, Kate L. Parent, Michael L. Heien, Todd W. Vanderah, Robin Polt, Scott J. Sherman, Torsten Falk

Research output: Contribution to journalArticle

Abstract

Objectives: Dopamine-replacement utilizing L-DOPA is still the mainstay treatment for Parkinson's disease (PD), but often leads to development of L-DOPA-induced dyskinesia (LID), which can be as debilitating as the motor deficits. There is currently no satisfactory pharmacological adjunct therapy. The endogenous opioid peptides enkephalin and dynorphin are important co-transmitters in the direct and indirect striatofugal pathways and have been implicated in genesis and expression of LID. Opioid receptor antagonists and agonists with different selectivity profiles have been investigated for anti-dyskinetic potential in preclinical models. In this study we investigated effects of the highly-selective μ-opioid receptor antagonist CTAP (> 1200-fold selectivity for μ- over δ-opioid receptors) and a novel glycopeptide congener (gCTAP5) that was glycosylated to increase stability, in the standard rat LID model. Results: Intraperitoneal administration (i.p.) of either 0.5 mg/kg or 1 mg/kg CTAP and gCTAP5 completely blocked morphine's antinociceptive effect (10 mg/kg; i.p.) in the warm water tail-flick test, showing in vivo activity in rats after systemic injection. Neither treatment with CTAP (10 mg/kg; i.p.), nor gCTAP5 (5 mg/kg; i.p.) had any effect on L-DOPA-induced limb, axial, orolingual, or locomotor abnormal involuntary movements. The data indicate that highly-selective μ-opioid receptor antagonism alone might not be sufficient to be anti-dyskinetic.

Original languageEnglish (US)
Article number149
JournalBMC research notes
Volume13
Issue number1
DOIs
StatePublished - Mar 12 2020

    Fingerprint

Keywords

  • Basal ganglia
  • Delta-opioid receptors
  • Levodopa
  • Mu-opioid receptors
  • Parkinson's disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this